Please login to the form below

Not currently logged in
Email:
Password:

In the Wild

This page shows the latest In the Wild news and features for those working in and with pharma, biotech and healthcare.

FDA halts study of Teva and Regeneron's pain drug fasinumab

FDA halts study of Teva and Regeneron's pain drug fasinumab

However, the updated results revealed what might be a dose-dependent increase in the risk of arthropathy with the drug. ... view the candidates still in trials as wild cards, potentially offering big rewards but also a having a high risk of failure.

Latest news

  • NICE backs BMS' Opdivo for melanoma NICE backs BMS' Opdivo for melanoma

    We welcome [the] decision from NICE, which is positive news for melanoma patients in the UK," said Johanna Mercier, general manager of BMS in the UK and Ireland. ... approval. The green light means that the cancer immunotherapy combination can be used in

  • New behavioural science comms consultancy launches New behavioural science comms consultancy launches

    New behavioural science comms consultancy launches. In the Wild will be led by managing director Andrew Martello. ... In the Wild's managing director Andrew Martello said: “ Our clients are innovators in the pharmaceutical industry who see the untapped

  • Erbitux betters Avastin in bowel cancer subgroup Erbitux betters Avastin in bowel cancer subgroup

    However, new data presented at the Congress suggests that Merck's drug may be superior in the subset of patients with RAS wild-type mCRC – a form of mCRC associated with ... overall survival and may in part explain why we are seeing the overall

  • Information seen as main future health issue

    All attendees highlighted the importance of behaviour change in the public, with individuals becoming empowered to make efforts and decisions regarding their own health. ... In all sessions, however, the most pressing matter in information proliferation

  • Tamiflu boosts Roche sales rise

    Roche is riding high on the back of strong demand for antiviral, Tamiflu, after reporting a 20 per cent rise in third quarter sales to SwFr 10.47bn ($8.23bn), beating ... ìThis is the wild card in the pack, î Roche pharmaceuticals unit head, William

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics